If you want to pick your own biotech stocks, rather than investing in a biotech-focused ETF or mutual fund, the author of today’s article advises… Read More »Biotech Bargains: 4 Names Trading Far Below Their Average Price Targets
As the unofficial winner of the COVID-19 vaccine race (along with partner Pfizer), BioNTech can be considered the No. 1 biotech stock. But the German… Read More »How The “No. 1 Biotech Stock” Is Expanding Its Footprint In The U.S.
The rapid spread of the hyper-contagious Delta variant of the coronavirus, along with the increasing need for treatments for other critical diseases, ensures a continued… Read More »3 Biotech Stocks With Promising Product Pipelines And More Than 170% Near-Term Upside Potential
Against the current backdrop for the biotech industry, comprised of continued efforts to fight COVID-19 as well as a focus on developing treatments for heretofore… Read More »These 2 Biotech Stocks Appear Attractively Cheap And Attractively Positioned For Solid Returns
Looking at the biotech sector right now, new drug approvals could gain momentum in the wake of the FDA’s approval of Biogen’s Alzheimer’s drug, mergers… Read More »3 Outperforming Biotech Stocks With Further Upside In The Back Half Of 2021
A clinical-stage biopharmaceutical company focused on the development of novel therapeutics and delivery methods for breast cancer and other breast conditions, as well as three… Read More »4 Biotech Stocks To Watch Heading Into July
“Five stocks for aggressive accounts that look to get share-count leverage on companies that have sizable upside potential” is what today’s article highlights – and… Read More »“Sizable Upside Potential”: 5 Smaller Cap Stocks For More Aggressive Investors
In the wake of the company disclosing in May that it would be delaying its Biologic License Application filing with the FDA for its key… Read More »Is The Sell-Off In This Biotech Stock A Buying Opportunity? Cathie Wood Thinks So.
The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm resulted in shares of the biotech rocketing higher – and the rest of the biotech sector went… Read More »Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
The biotech featured in today’s article, focused on a new scientific approach to tackling Alzheimer’s disease and other neurodegenerative disorders, is up 884% so far… Read More »A Promising Drug Candidate For Both Alzheimer’s And Parkinson’s Disease Could Drive This Surging Biotech Even Higher